The increasing incidence of carbapenemase-producing Enterobacterales is an imminent public health concern. Here, Terry Whalley highlights the importance of raising awareness of this among decision-makers in a healthcare environment, and discusses how practical and implementable screening could help trusts stay one step ahead of this global threat.
Antimicrobial resistance (AMR) presents a major challenge to healthcare across the world, threatening our ability to treat common infections and leading to prolonged hospital stays, mounting treatment costs and higher mortality rates.
The latest in a long line of drug-resistant pathogens are carbapenemase-producing Enterobacterales (CPE), and their increasing incidence presents an imminent public health concern that could drastically affect NHS trusts throughout the UK. Screening high-risk patients for CPE is an effective way to identify and isolate cases at an individual level, so that measures can be implemented to curb contamination and effectively prevent widespread outbreaks.
This article highlights the importance of raising awareness of CPE among decision-makers and board members in a healthcare environment, and discusses how practical and implementable screening could help trusts stay one step ahead of this global threat.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
